According to average age, sex, organ manifestations, and relapse rate, this cohort reflects the entire spectrum of patients with AASV including patients with various stages of kidney disease (14-17).
The present study investigates the predictive role of the endogenous NOS inhibitor ADMA and its stereoisomer SDMA for cardiovascular risk, all-cause mortality, and renal function in trial patients with AASV treated in a standardized fashion according to their disease stage.
(31) found a 9.5% CVE rate after 5 years in 42 patients with AASV (26% after 10 y).
The present study may have limitations, as the rather large vasculitis patient cohort is composed of smaller subgroups representing the different renal disease stages studied in the EUVAS therapeutic trials and as the numbers of patients in each subgroup were determined by the availability of serum samples and do not reflect the proportion of AASV patients with different disease stages seen in the clinic.
Adolescent and adult sexual victimization (AASV) is associated with several adverse psychological sequelae for SMW including post-traumatic stress, depressive symptomatology, and alcohol abuse (Gold et al., 2009; Heidt, Marx, & Gold, 2005; Morris 8t Balsam, 2003).
Most researchers examining the sexual sequelae of CSA for women have neglected to account for the possible additive effect of revictimization--i.e., experiencing CSA and subsequently experiencing AASV. This is an important omission because, based on the life course perspective (Elder, Johnson, and Crosnoe, 2003), early adverse experiences like CSA can catalyze a shift in women's life trajectories toward more negative health outcomes.
We compared the sexual well-being (behaviour, motivation, cognitive-affective responses) of women in a same-sex dating relationship with a history of CSA and/or AASV. Lemieux and Byers (2008) found that CSA involving only sexual touching was generally not related to these adverse sexual outcomes in heterosexual women.
Because of a possible role for ANCA in the pathogenesis of AASV, rituximab has been tried in patients who have failed with other treatments.
Current accepted treatment algorithms for AASV include CTX with corticosteroids and, once remission is achieved, maintenance therapy with AZA or MTX.
Summarizing the evidence regarding a pathogenic role for ANCA in AASV, it is likely that these antibodies are necessary but not sufficient for the development of the clinical syndromes.
The goals of treatment in AASV are initially induction of response and then maintenance of remission.
Traditionally, AASV, such as Wegener's granulomatosis, had mortality rates in excess of 80% within 3 years without adequate treatment.